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Abstract
Natural killer (NK) immune cells mediate antibody-dependent
cellular cytotoxicity (ADCC) by aggregating FcgRIIIA/CD16, con-
tributing significantly to the therapeutic effect of CD20 monoclo-
nal antibodies (mAb). In this study,we showthatCD16 ligationon
primary human NK cells by the anti-CD20 mAb rituximab or
ofatumumab stably impairs the spontaneous cytotoxic response
attributable to cross-tolerance of several unrelated NK-activating
receptors (includingNKG2D,DNAM-1, NKp46, and 2B4). Similar
effects were obtained from NK cells isolated from patients with
chronic lymphocytic leukemia in an autologous setting. NK cells
rendered hyporesponsive in this manner were deficient in the
ability of these cross-tolerized receptors to phosphorylate effector
signaling molecules critical for NK cytotoxicity, including SLP-76,
PLCg2, and Vav1. These effects were associated with long-lasting
recruitment of the tyrosine phosphatase SHP-1 to the CD16
receptor complex. Notably, pharmacologic inhibition of SHP-1
with sodium stibogluconate counteracted CD20mAb-inducedNK
hyporesponsiveness, unveiling an unrecognized role for CD16 as a
bifunctional receptor capable of engendering long-lasting NK
cell inhibitory signals. Our work defines a novel mechanism of
immune exhaustion induced by CD20 mAb in human NK cells,
with potentially negative implications in CD20 mAb-treated
patients where NK cells are partly responsible for clinical efficacy.
Cancer Res; 75(19); 1–12. 2015 AACR.
Introduction
Anti-CD20–based therapies represent a breakthrough in the
treatment of B-cell malignancies and autoimmune diseases. The
chimeric rituximab is considered the reference molecule for the
comparison of new-generation anti-CD20 mAbs designed to
reach enhanced clinical activity; among them, the fully human
ofatumumab, currently approved for relapsed or refractory chron-
ic lymphocytic leukemia (CLL), binds to a CD20 epitope different
from the rituximab-binding site (1, 2). Both rituximab and
ofatumumab belong to class I mAbs on the basis of their capa-
bility to redistribute CD20 molecules into lipid rafts (2).
Class I mAbsmay act throughmultiple mechanisms, including
the activation of complement-dependent cytotoxicity and the
recruitment of FcgRþ effector cells for antibody-dependent phago-
cytosis and natural killer (NK) cell–mediated antibody-depen-
dent cellular cytotoxicity (ADCC; refs. 1, 3–5).
Despite widespread treatment successes, the development of
resistance to anti-CD20mAbs, leading to a substantial decrease in
the immunotherapeutic efficacy and to high relapse rate, is a
major problem in patients with B-cell lymphomas (6). One
possible mechanism thought to contribute to a reduced thera-
peutic efficacy is the decreased ability to execute ADCC, mainly
attributed to CD16 downregulation upon recognition of anti-
CD20–coated targets (7–11).
NK cell–mediated ADCC is based on the recognition of IgG-
opsonized targets by the low-affinity receptor for IgG, FcgRIIIA/
CD16 (12). In human NK cells, CD16 has 2 extracellular Ig
domains, a short cytoplasmic tail, and a transmembrane domain
that enables its association with immune receptor tyrosine-based
activation motif (ITAM)-containing TCR-z and FceRI-g chains
(13). Besides CD16, the prototype of NK-activating receptors,
NK cells express a variety of activating receptors cooperating in
driving the natural cytotoxic response (14). Indeed, several acti-
vating receptors, including the lectin-like receptor NKG2D, the
signaling lymphocyte activation molecule (SLAM) family mem-
ber, 2B4, the Ig-like receptorDNAM-1 and the natural cytotoxicity
receptor (NCR), NKp46, recognize a multitude of ligands
expressed on infected and tumor cells, playing an important role
in antitumor response and immunosurveillance (15).
In the last few years, numerous evidences have revealed that the
reactivity ofNK cells is very plastic and support the idea thatmature
NK cells undergo continuous re-education (also called licensing or
tuning). With a mechanism that complements education via
inhibitory receptors, the sustained engagement of selected activat-
ing receptors, including NKG2D, NKp46, and KIR2DS1, has been
shown to downregulate NK cell responsiveness (16–19).
Here we have addressed whether engagement of CD16 by
exposure to anti-CD20 mAbs may lead to NK cell exhaustion.
We show that CD16 ligation on primary human NK cells by
rituximab- or ofatumumab-opsonized targets results in a
marked and persistent impairment of the spontaneous
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cytotoxic response due to the cross-tolerance of several unre-
lated NK-activating receptors, without affecting the ability to
secrete IFNg . Importantly, analogous observations were
obtained in NK cells from patients with CLL in an autologous
setting. We also provide evidences that in hyporesponsive NK
cells, stimulation of the cross-inhibited receptors resulted in the
defective tyrosine phosphorylation of signaling elements crit-
ical for NK cytotoxicity such as SLP-76, PLCg2, and Vav1, likely
imputable to the long-lasting recruitment of SHP-1 to CD16
receptor complex.
Materials and Methods
Patients and healthy donors
Peripheral blood mononuclear cells (PBMC) were obtained
from healthy donors of Transfusion Center of Sapienza Univer-
sity (Rome, Italy) or frompatientswithCLLofHematologyUnit,
S. Maria Goretti Hospital (Latina, Italy). The study was con-
ducted according to protocols approved by our local institu-
tional review board and in accordance with Declaration of
Helsinki. Written informed consent was obtained from all
patients. The diagnosis of CLL was based on criteria recom-
mended by the International Workshop on Chronic Lympho-
cytic Leukemia; the stage of disease was assessed according to the
Rai staging system (20). In all specimens, the percentage of
CD5þCD19þCLL cells wasmore than 80%. From each patient, a
part of PBMC was used to obtain primary cultured NK cells (see
below) and a portion was cryopreserved and stored at 160C.
The day before the experiment, samples were thawed, cultured
overnight in complete medium, and then checked for cell
viability by trypan blue staining. Only samples with viability
more than 90% were used.
Cell systems
Primary cultured human NK cells were obtained from healthy
donors or from CLL patients as previously described (21). The
experiments were performed on NK cells (CD3CD56þ) more
than 80% pure. When specified, NK cells were pretreated for 48
hours with recombinant human IL2 (200 U/mL; R&D Systems).
The following cell lines were used: the human CD20þ lympho-
blastoid, Raji, provided by Dr. F.D. Batista (Cancer Research UK,
London, UK); the thymic lymphocytic leukemia, HPB-ALL,
obtained from Dr. G. Scala (University "Magna Graecia" of
Catanzaro, Catanzaro, Italy; ref. 22); the murine thymoma,
BW5147, obtained formA.Moretta (University of Genoa, Genoa,
Italy; ref. 23); human lymphoblastoid Daudi and 721.221, T-cell
leukemia MOLT-4, erythroleukemia K562, and colon carcinoma
CaCo2 were all obtained from ATCC. NK-resistant targets murine
pro-B-cell line Ba/F3 and Ba/F3-MICA (stably expressing
MICA0019) cells were provided by Dr. L.L. Lanier (University
of San Francisco, San Francisco, CA; ref. 24); Ba/F3-PVR, Ba/F3-
CD48 transfectants were kindly provided byDr. A. Soriani andDr.
A. Zingoni (Sapienza University). Cells were authenticated (last
testing January–May 2014) by morphology, growth, and immu-
nophenotypic characteristics, biologic behavior according to the
provider recommendations, and tested for mycoplasma contam-
ination by EZ-PCR Mycoplasma Test Kit (Biological Industries).
All cell lines were and kept in culture for less than two consecutive
months.
Anti-CD20–mediated NK cell stimulation
Raji cells or primary CLLwere loadedwith 10 mg/mL of EZ-Link
Sulfo-NHS-SS-Biotin (Thermo Fisher Scientific) for 30minutes at
room temperature. Cells were then opsonized with rituximab
Figure 1.
Rituximab (RTX)- or ofatumumab (OFA)-opsonized target interaction inducesCD16downmodulation at comparable levels. A, IL2-activatedNKcellswere cocultured
for 90 minutes with rituximab (red)- or ofatumumab (green)-opsonized or not opsonized targets (blue) and CD16 surface expression was evaluated by
immunofluorescence and FACS analysis gating on CD56þ population. One representative of five independent experiments is shown. Gray histogram represents
isotype control mAb. B, IL2-activated NK cells were cocultured for the indicated times with rituximab or ofatumumab-opsonized or not opsonized
targets (ctrl), stained, and analyzed as in A. CD16 expression was calculated as follows: [mean fluorescence intensity (MFI) of the stimulated samples/MFI of not
stimulated sample]  100. Data from three independent experiments (mean  SEM) are shown. C, IL2-activated NK cells were cocultured for 60 minutes with
rituximab (NK/RAJI-RTX)- or ofatumumab (NK/RAJI-OFA)-opsonized targets. Fixed and permeabilized cells were stained with GAH and anti-CD16 mAb. A
representative image of conjugates (n ¼ 55) or isolated NK or Raji cells is shown. The overlap of merged and differential interference contrast (DIC) images of
conjugates is shown. Bar, 5 mm.
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(Roche) or ofatumumab (GlaxoSmithKline) by incubating for 20
minutes at room temperature with saturating anti-CD20 concen-
tration (1 mg/106).
Primary cultured NK cells were mixed [effector:target (E:T) ¼
2:1]with targets, brieflypelleted, and cocultured for 90minutes or
different times, where indicated. NK cells were then recovered by
negative selection on streptavidin-coated Dynabeads (Invitrogen,
Life Technologies). When specified, immunomagnetically isolat-
ed NK populations were replated in culturemedium, supplemen-
ted or not with IL2 (200 U/mL).
Evaluation of cytotoxic activity and IFNg release
To analyze cytotoxic activity, rituximab- or ofatumumb-expe-
rienced NK populations were assessed in a 4-hour 51Cr release
assay. IFNg was analyzed by commercial ELISA kit (Thermo
Scientific; for details, see Supplementary Data).
Statistical and densitometric analysis
Statistical significance between two groups was determined by
2-tailed, paired Student t test. Differences amongmultiple groups
were analyzed with one-way ANOVA using Prism 5 software
(GraphPad). Where indicated, values were expressed as mean
 SEM and differences were considered to be statistically signif-
icant when P < 0.05. Quantification of specific bands (pixel
intensity) was performed with ImageJ1.41o software (NIH,
Bethesda, MD).
Additional methods can be found in Supplementary Methods.
Results
NK cell interaction with anti-CD20–opsonized targets induces
CD16 internalization
To compare the kinetics of CD16 downmodulation induced by
two class I anti-CD20mAbs, we evaluated CD16 levels in primary
human NK cells upon interaction with rituximab- or ofatumu-
mab-opsonized CD20þ targets. Hereafter, in all experiments, we
used NK cells stimulated with not opsonized target as control
population. Our data (Fig. 1A and B) show a progressive CD16
downmodulation thatwas superimposable inNK cells interacting
with rituximab- or ofatumumab-opsonized targets. CD16 expres-
sion reached minimum levels (40% of control) in 2 hours of
interaction, keeping a plateau of downmodulation until 18-hour
stimulation (Fig. 1B).
Because both internalization and/or receptor shedding may
contribute to anti-CD20–induced CD16 reduction (25), we
evaluated CD16 dynamics by fluorescence microscopy (Fig.
1C). As compared with the ring pattern of unconjugated cells,
CD16 distributed in intracellular dots in NK cells interacting
with rituximab- or ofatumumab-opsonized targets, thus indi-
cating an internalization process. No evidence of anti-CD20
internalization was observed; instead, it appeared capped at cell
membrane, as reported by others (26), in some extent coloca-
lizing with residual surface CD16. Furthermore, by comparing
CD16 levels in fixed and fixed/permeabilized NK cells, we
observed that almost 50% of downmodulated CD16 was the
result of internalization occurring during opsonized target
interaction (Supplementary Fig. S1).
These data demonstrate that the interaction with rituximab- or
ofatumumab-opsonized targets similarly induces surface CD16
downmodulation, which is partially attributable to receptor
internalization.
NKcell interactionwith anti-CD20–opsonized targets results in
a marked defect of cytotoxic responses
We investigated the impact of the NK cell interaction with
opsonized targets on their cytolytic potential. Hereafter, "expe-
rienced NK cells" define primary cultured NK cells immuno-
magnetically isolated upon 90 minutes of coculture with ritux-
imab- or ofatumumab-opsonized targets. Cytotoxic activity
of anti-CD20 experienced NK cells was assayed against ritux-
imab-opsonized or -sensitive targets to test ADCC or sponta-
neous cytotoxicity, respectively. As expected, experienced NK
cells exhibit a reduced ability to execute ADCC (Fig. 2A), but,
more interestingly, we observed a marked impairment of
the cytotoxic activity toward a panel of sensitive targets, that
was comparable in rituximab- or ofatumumab-experienced
NK cells (Fig. 2A).
Because in our experiments the impact of rituximab or ofatu-
mumab on NK cell responsiveness was largely superimposable,
we focused our analysis on rituximab.
The analysis of the kinetics of anti-CD20–dependent hypor-
esponsiveness revealed that it was already evident after 30 min-
utes and reached a plateau between 90 and 180 minutes of
interaction with opsonized targets (Fig. 2B). We then addressed
the persistence of the hyporesponsiveness by testing the cytotoxic
activity of NK cells maintained in culture for different lengths
of time upon opsonized target detachment. Albeit a partial
rescue was observed, a clear reduction of the spontaneous
cytotoxicity persisted until 48 hours. Notably, when the same
effector population was preactivated and cultured in the pres-
ence of IL2, a progressive recovery of the cytolytic function that
paralleled CD16 re-expression was evident, being almost com-
plete after 48 hours (Fig. 2C).
These experiments demonstrate that CD16 downregulation
induced by rituximab- or ofatumumab-opsonized target interac-
tion is associated with a persistent defect of the cytotoxic
responses.
NK hyporesponsiveness involves the cross-tolerance of
different activating receptor systems
With the aim to investigate, at individual receptor level, wheth-
er anti-CD20–induced NK cell hyporesponsiveness could regard
selected activating receptors, we tested the ability of rituximab-
experienced NK cells to kill resistant targets (Supplementary
Fig. S2A) bearing individual receptor ligand, that is,MHCI-related
chain A (MIC-A), poliovirus receptor (PVR), or CD48, to explore
NKG2D-, DNAM-1-, or 2B4-dependent lysis, respectively; more-
over, we took advantage of BW5147 thymoma cell line whose
killing is mostly due to NKp46 triggering (Supplementary Fig.
S2B). Our findings show a significant defect of the cytotoxic
activity triggered by the different receptors analyzed demonstrat-
ing that rituximab-mediated CD16 aggregation cross-inhibits
multiple and unrelated activating receptor families (Fig. 2D,
Supplementary Fig. S2C).
To assess whether the defect of spontaneous cytotoxicity could
be related to the downmodulation of activating receptors
occurring during target interaction, we analyzed the expression
levels of a panel of activating and adhesion receptors. Unlike
CD16 expression, we did not observe significant differences in
rituximab-experienced NK cells with respect to control popula-
tion or to the NK cells that did not interact with target
cells (unstimulated; Fig. 2E). When we evaluated perforin
and granzyme B, we observed that cytolytic mediator levels in
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rituximab-experienced NK cells was similar to that of control
populations, leading us to exclude that the cytotoxic defect
depends on the depletion of lytic mediators (Fig. 2F). Analogous-
ly, the same rituximab-induced hyporesponsive phenotype was
also observed in the absence of IL2 stimulation (Supplementary
Fig. S3).
Rituximab-opsonized primary B-CLL cells tune-down CD16
expression and cytolytic potential in autologous NK cells
To extend our observations to NK cells of patients potentially
candidate to rituximab treatment, we analyzed 6 untreated
patients with CLL (Supplementary Table S1). Primary CLL cells
were opsonized with rituximab and allowed to interact with
autologous primary NK cells. Rituximab-experienced NK cells
were tested forCD16expression and for spontaneous cytotoxicity.
Our findings show that NK cell interaction with autologous-
opsonized leukemia cells induces a marked downmodulation of
CD16 receptor (Fig. 3A) that is associated with a relevant defect of
spontaneous cytotoxic activity against Raji cells and PVR-expres-
sing target cells (Fig. 3B and C).
Lytic granule secretion but not IFNg production is impaired in
rituximab-experienced NK cells
We sought to investigate whether the defective cytotoxic
activity could selectively involve different steps of the lytic
event (27, 28). Our data show that neither the ability to
form conjugates with targets nor the polarization of lytic
granules at cytolytic synapse (Fig. 4A and B) resulted impaired.
However, when we measured the ability to secrete lytic granules
in response to target stimulation by assessing CD107a surface
levels, we observed a significant defect of lytic granule exocy-
tosis in rituximab-experienced NK cells with respect to unsti-
mulated cells. Such impairment was observed in both CD16þ
and CD16 downregulated populations (Supplementary
Fig. S4). In line with our evidences of a normal lytic granule
content in hyporesponsive cells, degranulation induced by
phorbol 12-myristate 13-acetate (PMA) plus ionomycin
resulted unaffected (Fig. 4C).
We then explored the ability of rituximab-experienced NK cells
to secrete IFNg . We observed that NK cell stimulation with target
cells, with mAbs specific for the cross-inhibited receptors or with
IL2, induced a comparable amount of IFNg with respect to control
populations (Fig. 4D).
These data demonstrate that the hyporesponsive status involves
a selective defect of lytic granule exocytosis but not the ability to
produce IFNg .
Defect of SLP-76, PLCg2, and Vav1 tyrosine phosphorylation in
rituximab-experienced NK cells
Assuming that CD16 downregulation may subtract dose-lim-
iting signaling elements (29), we analyzed the phosphorylation
events downstream to the cross-inhibited receptors. On the basis
of our observation of a defective lytic granule exocytosis, we
focused our analysis on signaling pathways controlling granule
secretion at the cytolytic synapse. Our data demonstrate amarked
defect on tyrosine phosphorylation of SLP-76 at Y128 residue,
induced by CD16 itself or by NKp46, NKG2D, or DNAM-1
stimulation in rituximab-experienced NK cells. Concomitantly,
we also observed reduced levels of PLCg2 tyrosine phosphoryla-
tion at Y1217 residue. Similarly, receptor-induced Vav1 tyrosine
phosphorylation at Y160 residue was also reduced, although
some basal levels of tyrosine phosphorylation were evident in
rituximab-experienced cells (Fig. 5A and B). Conversely, in hypor-
esponsive cells, Akt and Erk phosphorylation downstream
cross-inhibited receptors resulted unaffected (Fig. 5C).
These results demonstrate that in rituximab-experienced NK
cells tyrosine phosphorylation of SLP-76, PLCg2, and Vav1,
downstream to activating receptors is impaired.
Recruitment of SHP-1 tyrosine phosphatase to CD16 receptor
complex upon rituximab stimulation
The defective tyrosine phosphorylation of SLP-76, PLCg2, and
Vav1 led us to hypothesize the involvement of a tyrosine phos-
phatase coupled to CD16. We sought to analyze whether CD16
would be coupled to SHP-1/2 upon rituximab stimulation.
Immunoblot analysis of CD16z chain immunoprecipitates
revealed that rituximab stimulation induces a delayed and
long-lasting association of SHP-1 to phosphorylated CD16z
chain reaching maximal levels after 60 minutes of stimulation.
Notably, the ability of z chain to recruit SHP-1 was inversely
proportional to its tyrosine phosphorylation levels: indeed, SHP-
1 was not detectable at 5-minute stimulation, when z chain
Figure 2.
Anti-CD20–experiencedNK cells have a reduced cytolytic potential involving the cross-tolerance of different activating receptors. A, top, IL2-activatedNK cellswere
cocultured for 90 minutes with biotinylated rituximab (RTX)- or ofatumumab (OFA)-opsonized or not opsonized (ctrl) targets and immunomagnetically
isolated. Specific lysis from a single representative experiment of five performed is shown. Bottom, lytic units (LU) from five independent experiments performed
as in top are shown. Bars representmedian and 10–90percentile.  ,P<0.05;  ,P<0.01;  ,P<0.0005, repeated-measures ANOVAwith Tukey post-test correction.
B, IL2-activated NK cells were cocultured with biotinylated rituximab-opsonized or not opsonized (ctrl) Raji cells. For each time of stimulation, NK cells were
immunomagnetically isolated and tested toward Raji cells. Data are presented as relative reduction of LU with respect to ctrl from three independent experiments
(mean  SEM). C, untreated or IL2-activated NK cells were cocultured for 90 minutes with biotinylated rituximab-opsonized or not opsonized (ctrl) Raji cells, and
immunomagnetically isolated. NK cells were then cultured for the indicated times with or without IL2 and assayed either for cytotoxic activity toward Raji cells or for
CD16 surface expression. Data are presented as relative value of LU and CD16 levels with respect to control from three independent experiments (mean  SEM).
D, IL2-activatedNKcellswere left unstimulatedor cocultured for 90minuteswith biotinylated rituximab-opsonizedor not opsonized (ctrl) targets, immunomagnetically
isolated, and tested toward the indicated targets. LU from five independent experiments are shown. Bars, median and 10th to 90th percentile.  , P < 0.05;
 , P < 0.01, repeated-measure ANOVA with Tukey post-test correction. E, NK cells as in D were stained with receptor-specific mAbs. Assuming as 100% the
meanfluorescence intensity (MFI) of unstimulated samples, receptor expressionwas calculated as follows: (MFI of the stimulated samples/MFI of unstimulated samples)
 100. Data from five independent experiments (mean  SEM) are shown.  , P < 0.0005, repeated-measures ANOVA with Tukey post-test correction.
F, NK cells as in D were fixed, permeabilized, and stained as indicated. Left, histograms relative to a representative experiment are showed. Unstimulated,
dashed line; control, dotted line; rituximab, unbroken line. Gray histogram represents isotype control mAbs. Right, expression levels were calculated as for E. Data
from three independent experiments (mean  SEM) are shown. No significant (n.s.) differences were observed, Friedman with Duns' post-test correction.
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was maximally phosphorylated, but appeared upon 30 min-
utes, further increasing at 60 minutes of rituximab stimulation
(Fig. 6A). In contrast, we did not observe any evidences of SHP-
2 recruitment. Intriguingly, the aggregation of CD16 obtained
with anti-CD16 (B73.1) mAb did not induce a detectable SHP-1
recruitment. Of note, in such aggregation conditions, although
a very efficient CD16 downmodulation occurred (Fig. 6B), NK
cells preserved their cytolytic potential (Fig. 6C).
These experiments show that rituximab-mediated but not anti-
CD16 mAb-mediated stimulation induces the recruitment of
SHP-1 to CD16 receptor complex.
Pharmacologic inhibition of SHP-1 activity counteracts
rituximab-induced NK hyporesponsiveness
The hypothesis that SHP-1 phosphatase activity may be
responsible for the functional impairment was tested by inhi-
biting SHP-1 with SSG, which has been shown to be the most
sensitive tyrosine phosphatase (30, 31). Because SHP-1 activity
classically mediates the inhibitory signals downstream MHCI
inhibitory NK receptors in co-aggregation conditions (32), we
avoided that their engagement would occur during target rec-
ognition by using MHCI-negative Daudi cell line. Our data
show that in SSG-pretreated NK cells, the defect of spontaneous
cytotoxicity in rituximab-experienced NK cells was partially but
significantly prevented. This effect was observed at variable
degree in all donors tested (Fig. 6D), indicating that SHP-1
acts in limiting the cytotoxic responses in rituximab-experi-
enced NK cells.
Discussion
The central observation of our report is that preligation of
CD16 by anti-CD20 mAbs reduces the ability of NK cells to kill
target cells; indeed, we demonstrate that the outcome of NK cell
interactionwith rituximab- or ofatumumab-opsonized targets is a
comprehensive reduction of both Ab-dependent and -indepen-
dent cytotoxic potential. SuchNKhyporesponsive status is almost
fully establishedupon30minutes ofCD16 ligation andpersists at
least until 48 hours of stimulation. Our data highlight that the
hyporesponsiveness does not involve the ability to secrete IFNg in
response to the cross-inhibited receptors. This observation is not
really surprising, taking into account the uncoupling of the
signaling pathways and molecular machinery leading to the
activation of the cytolytic program or to the production of
cytokines, including IFNg (33).
The impairment of ADCC response can easily be explained by
CD16 downmodulation induced by the stimulation of NK cells
with anti-CD20–opsonized targets, which is only partially attrib-
utable to receptor internalization; such finding complements
recent observations demonstrating that rituximab stimulation,
through activation of metalloprotease-17 (ADAM17), promotes
CD16 shedding (25).
Figure 3.
NK cell interaction with rituximab (RTX)-opsonized autologous CLL cells induces CD16 downregulation and NK hyporesponsiveness. NK cells from six patients
with CLL were left unstimulated or cocultured for 90 minutes with biotinylated rituximab-opsonized or not opsonized (ctrl) primary CLL cells and
immunomagnetically isolated. NK cellswere stainedwith anti-CD16mAb (A) or tested in a 4-hour 51Cr release assay (B). C, lytic units (LU) from the samepatients are
shown in A and B. Bars represent median and 10–90 percentile. , P < 0.0005;  , P < 0.01, repeated-measure ANOVA with Tukey post-test correction.
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Less expected is the finding that anti-CD20–mediated CD16
stimulation also promotes amarked reduction of the ability ofNK
cells to kill sensitive targets attributable to the cross-inhibition of
multiple unrelated activating receptors, including NKG2D, 2B4,
NKp46, andDNAM-1,which are coupled toboth ITAM- andnon–
ITAM-containing signaling adaptors (14, 15). The observation
that preligation of CD16 induces NK cell hyporesponsiveness is
strengthened by the finding that the exposure of primary NK cells
from patients with CLL to rituximab-opsonized autologous leu-
kemia cells induces a significant reduction of natural killing
potential. Importantly, our observations might account for the
marked defect of spontaneous cytotoxicity in ex vivo isolated NK
cells from patients with diffuse large B-cell lymphoma treated
with rituximab (34). Furthermore, the cooperation of activating
receptors, stimulated by novel therapeutic mAbs or by tumor
ligands, in determining the overall response to tumor targeting
mAbs have been recently highlighted (35–37); their cross-toler-
ance induced by rituximab treatment may negatively affect the
clinical outcome.
We also provide evidences that the cytotoxic defect is not
attributable to an altered phenotype or to depletion of cyto-
lytic mediators: indeed, the levels of activating and adhesion
receptors as well as of perforin and granzyme B are largely
unaffected.
Weweremuch intrigued inunderstanding themolecular basis of
NK hyporesponsiveness induced by CD16 preligation. In natural
killing, a mechanistic role of CD16 has been defined through the
demonstration that CD16-dependent proximal signaling elements
may be exploited by other activating receptors (29). We explored
the possibility that the persistent engagement of CD16may lead to
the inhibition of critical molecules acting in signal integration
downstream to activating receptors. On this regard, the adaptor
protein SLP-76 has been shown to orchestrate the formation of a
molecular platform allowing the tyrosine phosphorylation of
Figure 4.
Lytic granule exocytosis but not IFNg production is impaired in rituximab (RTX)-experienced NK cells. NK cells were left unstimulated or were cocultured
for 90 minutes with biotinylated rituximab-opsonized or not opsonized (ctrl) targets and immunomagnetically isolated. A, CFSEþ NK cells were allowed to bind to
PKH26þ Raji for 30 minutes. The percentage of conjugates was determined by flow cytometry. Data are presented as mean  SEM of three independent
experiments. B, NK cells were mixed to CMAC-labeled Raji cells for 15 minutes. Cell conjugates were fixed, permeabilized, and stained with anti-perforin mAb. The
percentage of conjugates containing polarized granuleswas analyzed on randomly acquired fields of three independent experiments (mean SEM; n¼ 55 conjugates).
C, NK cells were stimulated with the indicated targets or with PMA plus ionomycin. The percentage of CD107aþ cells was analyzed by flow cytometric gating
on CD56þ cells. Data are presented as mean SEM of three independent experiments.  , P < 0.05, paired Student t test. D, NK cells were stimulated with the indicated
targets or plastic-immobilized mAbs or with IL2. After 18 hours, supernatants were collected and assessed for IFNg levels. Data are presented as mean  SEM of
three independent experiments.
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critical signaling elements such Vav1 and PLCg2 (14, 38). Our
data show in hyporesponsive NK cells a marked defect in SLP-
76, PLCg2, and Vav1 tyrosine phosphorylation induced by
the stimulation of cross-inhibited receptors or by CD16
itself. Furthermore, we observed that the activation of PI3K
and MAPK-dependent signals resulted unaffected. These
data, in the context of our observation of a selective defect of
lytic granule exocytosis with normal granule polarization in
rituximab-experienced NK cells, recapitulate the dichotomy of
molecular signals governing polarization versus degranulation:
the pathway sequentially involving PI3K/Rac1/Pak1/MEK/
ERK1/2 has been referred as pivotal for granule polarization,
whereas PLCg/calcium-dependent signals are the hallmark for
their secretion (27, 28, 39).
Figure 5.
Defect of SLP-76, PLCg2, and Vav1
tyrosine phosphorylation in rituximab
(RTX)-experienced NK cells. NK cells
were cocultured for 90 minutes with
biotinylated rituximab-opsonized or
not opsonized (ctrl) targets and
immunomagnetically isolated.
Recovered NK cells were stimulated
with anti-CD16, anti-NKG2D, anti-
DNAM-1, anti-NKp46, or isotype-
matched anti-CD56 mAb (ctrl mAb)
followed by GAM F(ab0)2. An equal
amount of proteins was
immunoblotted with Abs anti-
phosphorylated proteins of the
indicated specificity. The same
membranes were reprobed as
indicated for sample normalization.
For each phosphorylated protein,
control and rituximab membranes
were derived from the same film. One
representative experiment of three
performed is shown. B, data from
three independent experiments as in A
are presented as min-to-max bar
graphs with average mean lines.  , P
< 0.0005;  , P < 0.01;  , P < 0.05,
paired Student t test. C, NK cell lysates
were immunoblotted with the
indicated Abs. The numbers between
lanes represent phosphorylation
levels of the indicated proteins after
normalization with the relative total
levels.
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We firstly provide evidences of the involvement of SHP-1
in CD16-dependent cross-tolerance of activating receptors.
Indeed, we observe that rituximab stimulation promotes
the recruitment of SHP-1 phosphatase, but not SHP-2, to
the tyrosine phosphorylated CD16 z chain. This recruitment
was delayed (30 minutes) and long-lasting (1 hour) with a
time course drastically different from the classical rapid
recruitment of SHP-1 by ITIM-containing MHCI inhibitory
receptors in condition of co-aggregation with activating
receptors (32).
We propose that the recruitment of SHP-1 to targeted CD16
promotes its accumulation at the plasma membrane, reaching a
Figure 6.
Rituximab (RTX) stimulation induces
SHP-1 recruitment to CD16z chain.
SHP-1 inhibition counteracts
rituximab-dependent NK
hyporesponsiveness. A, NK cells were
left unstimulated (0) or stimulated
with rituximab- or anti-CD56 F(ab0)2
(ctrl-Fab0)-coated polystyrene
beads, or anti-CD16
mAb followed by GAM F(ab0)2 for
the indicated times. Whole lysate of
unstimulated sample (lysate) or IgG1
or z chain immunoprecipitates were
run on 8% (top) and 15% (middle
and bottom) SDS-PAGE and
immunoblotted with the indicated
mAbs. All lanes were from the same
experiment but were noncontiguous.
B, NK cells were left unstimulated or
were cocultured for 90 minutes with
biotinylated rituximab-opsonized or
not opsonized (ctrl) targets and
immunomagnetically isolated.
Alternatively, NK cellswere stimulated
with anti-CD16, B73.1 mAb for 90
minutes. NK cells were stained with
anti-CD16 mAb (ctrl and rituximab
populations) or with phycoerythrin-
conjugated GAM (B73.1 population).
CD16 expression was calculated as
in Fig. 2E. Data are presented as mean
 SD of three independent
experiments. C, specific lysis is
presented as mean  SD of three
independent experiments. D, NK cells
were left untreated (w/o SSG)
or treated for 4 days with SSG
(50 mg/mL). Cells were cocultured for
90 minutes with biotinylated
rituximab-opsonized or not
opsonized (ctrl) targets and
immunomagnetically isolated.
Specific lysis of six individual donors
and lytic units (LU) of the same donors
are shown. Bars represent median and
10–90 percentile.  , P < 0.05, paired
Student t test.
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threshold level that would allow the dephosphorylation of signal-
ing proteins, thus desensitizing activating receptors subsequently
stimulated (Figure 7). Indeed, both SLP-76 and Vav1 have been
shown to be key targets of SHP-1 triggered by killer inhibitory
receptors in NK cells (40, 41). We are currently investigating by
imaging approaches the spatial coordination of inhibitory signals;
on this purpose, a recent report demonstrated a raft-dependent co-
segregation of SHP-1 with signaling effectors into intracellular
clusters (called inhibisomes), providing an appropriate scaffold
for substrates interaction during inhibitory process (42). A func-
tional role of SHP-1 in mediating CD16-dependent hyporespon-
siveness is indicated by our observation that SHP-1 pharmacologic
inhibition with SSG, known to inhibit SHP-1 (30), significantly
interferes with rituximab-induced inhibitory responses.
On the basis of our data showing a long-lasting NK exhaus-
tion following rituximab stimulation, we cannot exclude that a
transcriptional or a posttranscriptional modulation may con-
tribute to NK hyporesponsiveness. Accordingly, the recovery of
NK responsiveness driven by IL2 treatment, strictly associated
to the restoration of CD16 levels, may indicate a de novo gene
expression and protein synthesis. Indeed, recent data demon-
strated that the calibration of NK cell reactivity is subjected to a
genetic-based tuning attributable to transcription factor mod-
ulation (19, 43).
Strikingly and in contrast with rituximab, receptor ligation
by anti-CD16 mAb was ineffective in promoting SHP-1 recruit-
ment. Notably, in the same stimulation conditions, the ability
of NK cells to kill sensitive targets was preserved, indicating
a relationship between aggregation conditions and the ability
to promote inhibitory signal toward heterologous receptors.
It would be interesting to address whether other therapeutic
mAbs, acting through the triggering of ADCC, such as trastu-
zumab and cetuximab or with improved affinity for CD16,
as obinutuzumab, may also mediate a CD16-dependent inhib-
itory signal.
Overall our findings are in line with the emerging paradigm
considering that the targeting of some classically activating Fc
receptors in myeloid cells with low-avidity ligands, paradoxically
transmit inhibitory signals, through the recruitment of SHP-1,
leading to the inhibition of a number of innate immune responses
(44–46).
We identify here a mechanism of exhaustion of NK cells likely
contributing to the resistance and/or to the development of a
refractory status to rituximab-containing regimens leading to
disease relapse or progression (6). Furthermore, our data may
provide insights on the high frequency of viral reactivation in
rituximab-treated patients, which may implicate an NK hypor-
esponsiveness leading to reduced immunosurveillance (47).
Figure 7.
Proposed CD16-dependent inhibitory
signal: spatiotemporal integration.
CD16 aggregation by anti-CD20–
opsonized targets results in a
persistent SHP-1 recruitment to
phosphorylated z chain, which
mediates the dephosphorylation of
critical signaling elements
downstream activating receptors
subsequently engaged, leading to the
impairment of granule exocytosis.
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